Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCLARITHROMYCIN (clarithromycin) by Molecular Devices is cytochrome p450 3a4 inhibitors [moa]. Approved for mild to moderate infections caused by susceptible isolates due to haemophilus influenzae, moraxella catarrhalis, streptococcus pneumoniae [see indications and 16 more indications. First approved in 2022.
Drug data last refreshed 21h ago
Cytochrome P450 3A4 Inhibitors
Macrolide Antimicrobial
Worked on CLARITHROMYCIN at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Drug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin
A Study to Learn if Study Medicines Called Cyclosporine and Clarithromycin Affect How the Body Processes the Other Study Medicine Called PF-07328948 in Healthy Adults
Drug-Drug Interactions Between TNP-2198 and Midazolam, Clarithromycin
A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants
Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo